2 completed, 2 terminated. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 2, Terminated 2 |
Follow Wilson Disease: new trials by email Literature Review of Wilson Disease trials Research Report on Wilson Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease ALXN1840, Standard of Care - Wilson Disease | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 40 | 2021-09-13 | 2024-10-23 |
| Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease Penicillamine (D1-W12), TETA 4HCL (W12-60), Penicillamine (W12-W60) - Wilson Disease | Phase 3 | Completed | Orphalan | 77 | 2018-09-03 | 2025-07-02 |
| Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease ALXN1840, SoC Therapy - Wilson Disease | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 214 | 2018-02-22 | 2024-06-17 |
| Study of Tetrathiomolybdate in Patients With Wilson Disease tetrathiomolybdate, trientine - Wilson Disease | Phase 3 | Completed | National Center for Research Resources (NCRR) | 90 | 1994-01-01 | 2006-05-09 |
Hepatolenticular Degeneration (4) · Metabolism, Inborn Errors (1) · Rare Diseases (1)
Basal Ganglia Diseases (4) · Brain Diseases (4) · Brain Diseases, Metabolic (4) · Brain Diseases, Metabolic, Inborn (4) · Central Nervous System Diseases (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Digestive System Diseases (4) · Genetic Diseases, Inborn (4) · Heredodegenerative Disorders, Nervous System (4) · Liver Diseases (4) · Metabolic Diseases (4) · Metal Metabolism, Inborn Errors (4) · Movement Disorders (4) · Nervous System Diseases (4) · Neurodegenerative Diseases (4)
tetrathiomolybdate (2) · Penicillamine (1) · Standard of Care (1) · Trientine (1)
Alexion Pharmaceuticals, Inc. (2) · National Center for Research Resources (NCRR) (1) · Orphalan (1)
France (3) · Germany (3) · Poland (3) · United States (3) · Australia (2) · Denmark (2) · Japan (2) · South Korea (2) · Spain (2) · United Kingdom (2) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1)
Eugene S. Swenson, M.D., Ph.D. (1) · Eugene S. Swenson, MD, PhD (1) · George J. Brewer (1)
PMID 36183738, PMID 39139457, PMID 41831608
2017 (1)